Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Rhea-AI Summary

Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical firm focused on T cell-driven therapies, will present at several conferences in February and March 2023. Notable events include the SVB Securities Global Biopharma Conference on February 15 at 4:10 PM Eastern and the BioCom Global Partnering and Investor Conference from February 28 to March 2. The company is advancing a pipeline of therapies for chronic inflammatory diseases, targeting conditions like atopic dermatitis, asthma, and ulcerative colitis. Key product candidates include CBP-201 and CBP-307.

SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting, and hosting one-on-one meetings, at the following conferences in February and March 2023:

• SVB Securities Global Biopharma Conference, February 15 at 4:10 pm Eastern/1:10pm Pacific. To view the presentation live please, follow this link: https://wsw.com/webcast/svb8/cntb/1610037
  A replay will be available for 90 days, until April 17.

• BioCom Global Partnering and Investor Conference, February 28 – March 2, at the Lodge at Torrey Pines, La Jolla, Calif.
  

About Connect Biopharma Holdings Limited

Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD.

For more information, please visit: https://www.connectbiopharm.com/

INVESTOR CONTACT:
Ina McGuinness
805.427.1372
imcguinness@connectpharm.com

MEDIA CONTACT:
Deanne Eagle
917.837.5866
Deanne@mcguinnessIR.com 

FAQ

What conferences is Connect Biopharma presenting at in February 2023?

Connect Biopharma will present at the SVB Securities Global Biopharma Conference on February 15 and the BioCom Global Partnering and Investor Conference from February 28 to March 2.

What is the date and time of Connect Biopharma's presentation at the SVB Securities Conference?

The presentation at the SVB Securities Global Biopharma Conference is scheduled for February 15, 2023, at 4:10 PM Eastern.

What is Connect Biopharma's lead product candidate for treating atopic dermatitis?

Connect Biopharma's lead product candidate for atopic dermatitis is CBP-201, which targets the interleukin-4 receptor alpha.

What product candidate is in development for ulcerative colitis?

CBP-307 is being developed by Connect Biopharma as a treatment for ulcerative colitis.

How can I watch the SVB Securities Conference presentation by Connect Biopharma?

The presentation can be viewed live at the following link: https://wsw.com/webcast/svb8/cntb/1610037. A replay will be available until April 17, 2023.